According to these criteria, an abnormal Core 1 biomarker result is sufficient to establish a diagnosis of AD, whereas later changes in Core 2 biomarkers (as non-phosphorylated mid-region tau fragments in biofluid and tau PET) are useful to provide prognostic information, and, if abnormal, increase confidence that AD is contributing to symptoms. This evidence concerns the gene MAPT and Alzheimer disease.